Longevity & AgingPress Release

FDA Approves Neladalkib for Previously Treated ALK-Positive Lung Cancer

The FDA granted accelerated approval to neladalkib after alectinib or multiple prior therapies. Response rates reached 49% and 32%, with liver toxicity common.

Wednesday, November 18, 2026 0 views
Published in MedPage Today
Article visualization: FDA Approves Neladalkib for Previously Treated ALK-Positive Lung Cancer

Summary

The FDA has granted accelerated approval to neladalkib (Nelkarmi), a third-generation ALK inhibitor, for advanced ALK-positive non-small cell lung cancer that has already been treated. It is the seventh approved drug in this field. The approval rests on a single-arm phase I/II trial of 222 patients. Among 67 patients who had received only alectinib, 49% responded. Among 155 patients who had received two or more ALK inhibitors plus platinum chemotherapy, 32% responded. Responses were less frequent in people previously treated with lorlatinib (26%) than in those who had not (46%). Median progression-free survival was 5.7 months overall and 14.5 months without prior lorlatinib. Liver enzyme elevations were the most common side effect, occurring in nearly half of patients. Accelerated approval means confirmatory evidence is still needed. A phase III first-line trial, ALKAZAR, is ongoing.

Detailed Summary

Targeted therapy has turned ALK-positive lung cancer from a fast-moving disease into one many patients live with for years, often cycling through several drugs. Because resistance eventually emerges, each new option that extends control matters for the length and quality of life in this population.

The FDA granted accelerated approval to neladalkib (Nelkarmi), a third-generation ALK tyrosine kinase inhibitor, for unresectable locally advanced or metastatic ALK-positive non-small cell lung cancer. It is indicated after alectinib, or after at least two prior ALK inhibitors and platinum-based chemotherapy. It is the seventh approved agent in the field.

The evidence comes from the single-arm phase I/II ALKOVE-1 trial in 222 patients. In 67 patients with prior alectinib only, the response rate was 49%, and 76% of responders had a response lasting at least 6 months. In 155 more heavily pretreated patients, 32% responded, with 69% of responses lasting at least 6 months. About half of responders in each cohort had responses lasting 12 months or more. Prior lorlatinib exposure reduced the response rate to 26%, versus 46% without it. Median progression-free survival was 5.7 months overall and 14.5 months in lorlatinib-naive patients. A third of patients with brain metastases had objective responses.

Safety matters. Elevated liver enzymes occurred in almost half of patients, and grade 3 or higher in 15-20%. Other common events included musculoskeletal pain, constipation, taste changes, peripheral neuropathy, edema and fatigue. Warnings cover liver, kidney and eye toxicity, creatine phosphokinase elevation and embryo-fetal toxicity.

Practically, this gives oncologists another option after alectinib, and possibly after lorlatinib, though an invited discussant called activity relatively modest. Caveats: the trial had no comparator arm, so survival benefit versus other therapies is unproven. Accelerated approval depends on confirmatory data, and the phase III ALKAZAR first-line trial is still running. The figures come from a news report and company press release, so check the label and trial publications.

Key Findings

  • Accelerated FDA approval rests on single-arm phase I/II ALKOVE-1 (222 patients), not a randomized comparison.
  • Response rate was 49% after alectinib alone and 32% after two or more ALK inhibitors plus chemotherapy.
  • Prior lorlatinib lowered response rate to 26% versus 46%; median PFS 5.7 versus 14.5 months in lorlatinib-naive patients.
  • A third of patients with brain metastases had objective responses.
  • Liver enzyme elevation affected nearly half of patients, grade 3 or higher in 15-20%; label warns of liver, kidney, eye toxicity.

Methodology

News report from MedPage Today on an FDA accelerated approval, drawing on a GSK press release and ASCO 2026 data. The underlying evidence is a single-arm, open-label phase I/II trial with response rate and duration of response as endpoints; progression-free survival is descriptive without a control arm. Reporting is secondhand and includes an independent discussant's comment.

Study Limitations

Single-arm data cannot show survival benefit over alternatives, and response and progression-free survival are surrogates for overall survival and quality of life. The article is truncated and lacks full safety detail, discontinuation rates and confirmatory plans. Verify against the FDA label and ALKOVE-1 publications.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: